Sbir phase i: developing bioconjugation and preparation of 18F-biomolecules for pet imaging
Ended Project Grant Awarded Last action
- Award ID
- 2124459
- Recipient
-
Theracea Pharma LC UEI KSNLTEALRQL5
- Awarding agency
-
National Science Foundation
- Obligated
- $256,000
Award facts
- Assistance listing
- 47.084 NSF Technology, Innovation, and Partnerships
- Completion date
- Originally
- Place of performance
- Tucson, AZ 85719, USA
Award details come from USAspending.gov.
About this award
The National Science Foundation awarded Theracea Pharma LC a $256,000 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop bioconjugation and preparation of fluorine-18 biomolecules for positron emission tomography (PET) imaging. The grant period runs from August 15, 2021 through July 31, 2023 in Tucson, Arizona. Under this award, Theracea Pharma LC will work to advance science and engineering research and innovation leading to breakthrough technologies as well as solutions to national challenges through developing methods for labeling biomolecules with radioactive fluorine-18 for use in PET imaging procedures. The funding will support Theracea Pharma LC's work in bioconjugation chemistry and production of PET radiotracers over the two year grant period.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $256,000 |
Quick answers
Who received award 2124459?
2124459 was awarded to Theracea Pharma LC by National Science Foundation on August 15, 2021.
How much is award 2124459 worth?
$256,000 has been obligated on 2124459.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award